Yes. But at this point I would **not keep adding features**. I see about **four remaining improvements with genuinely high scientific value**. After those, additional complexity is more likely to hurt than help.

The most important one is a conceptual upgrade to how we represent heterogeneous experiments.

## 1. Treat technology as an **observation operator**, not a biological covariate

Right now we have been thinking approximately:

\[
X + \text{assay context} \rightarrow z_{\text{biology}}.
\]

I think the cleaner formulation is:

\[
\boxed{
z_{\text{biology}}
\;\xrightarrow{\text{measurement process } O_t}\;
X_{\text{observed}}
}
\]

and inference runs in the opposite direction:

\[
\boxed{
q(z_{\text{biology}}\mid X_{\text{observed}},O_t)
}
\]

Here \(O_t\) describes how technology \(t\) observes biology.

For example, even though FHRA showed every current matrix contains all 4,096 vocabulary genes, two technologies can still differ in:

- capture efficiency;
- dropout/count sampling;
- relative sensitivity;
- nucleus versus whole-cell composition;
- sequencing depth;
- technical variance.

So their masks can both be:

\[
M=(1,1,\ldots,1)
\]

while their **observation processes are still very different**.

That distinction is probably more important for our current real foundation corpus than structural missingness.

Conceptually:

```text id="rsbqf1"
             UNDERLYING BIOLOGY
                    z
                    │
       ┌────────────┼────────────┐
       │            │            │
       ▼            ▼            ▼
    assay A      assay B      assay C
      O_A          O_B          O_C
       │            │            │
       ▼            ▼            ▼
     counts       counts       counts
```

The model's job is to recover a compatible belief about \(z\), while knowing which observation operator produced the evidence.

This is much cleaner than putting a free `dataset_id` embedding into the biology encoder.

### What I would actually allow into \(O_t\)

Things with physical/experimental meaning:

- scRNA versus snRNA;
- platform/chemistry;
- measured vocabulary;
- sequencing depth;
- detected-gene characteristics;
- count-split estimated noise properties;
- other documented acquisition characteristics.

Not:

- donor ID;
- arbitrary matrix ID;
- unrestricted dataset embedding.

That makes the system more likely to transfer to a **new dataset it has never seen**, provided we can describe how that experiment measures RNA.

---

# 2. Make a precise distinction between **invariance and legitimate biological change**

We should not ask the state to be invariant to everything.

We want:

### Invariant—or approximately invariant—to

```text id="2hfokd"
measurement realization
sequencing noise
technical replicate
irrelevant assay differences
```

### But sensitive/equivariant to

```text id="wpbg12"
cell state
cell type
tissue environment
brain region
real donor biology
age-related biology
other genuine molecular context
```

This gives us a much better qualification rule.

For the same biological cell:

\[
z_{\text{count split A}}
\approx
z_{\text{count split B}}.
\]

For compatible biology measured by different technologies:

\[
z_{\text{tech A}}
\approx
z_{\text{tech B}}
\]

to the extent the biological states really are comparable.

But for a biologically different cell:

\[
z_1 \neq z_2
\]

even if making them different reduces “batch mixing.”

This is why I would **strongly avoid an objective like “make technology impossible to predict.”**

The right question is:

> After controlling for comparable biology, how much unnecessary technology information remains?

That is far safer.

---

# 3. There is an important issue with the 160-D basis we haven't discussed enough: **axis stability**

This may actually matter a lot for our uncertainty model.

Imagine we fit the 160-D basis using one set of TRAIN donors:

```text id="303x89"
basis A
```

and fit it again after leaving out different donors:

```text id="p5x61f"
basis B
```

The overall 160-dimensional **subspace** could be almost identical while individual axes rotate:

```text id="zkexi8"
A1 ≈ combination of B1+B2
A2 ≈ another combination of B1+B2
```

That is not necessarily a problem for representation.

But it becomes a problem if we say:

\[
\sigma_1^2,\sigma_2^2,\ldots,\sigma_{160}^2
\]

are meaningful coordinate-specific biological uncertainties.

Because if the axes themselves are unstable, coordinate-specific uncertainty is partly arbitrary.

### So before freezing the real state basis, I would test

Across donor-balanced resamples / leave-donor-group-out fits:

- principal angles between 160-D subspaces;
- canonical correlations;
- Procrustes-aligned similarity;
- individual coordinate stability;
- eigenvalue gaps.

This leads to a potentially important outcome.

If:

```text id="11372l"
subspace very stable
individual axes stable
```

excellent.

But if:

```text id="romks5"
subspace stable
axes rotate within groups
```

then we should treat those groups as **stable subspaces rather than individually meaningful coordinates**.

That may even suggest uncertainty should be reported over small stable blocks rather than pretending every PCA coordinate has an independent biological interpretation.

This is a better scientific reason for correlation/block structure than merely fitting covariance because it improves NLL.

And we can determine it **without neural training**.

---

# 4. Biological uncertainty should be defined by an **evidence-response curve**, not one arbitrary mask

I liked our earlier teacher/student formulation, but I think we can improve it further.

Instead of:

```text id="2a4z6e"
100% evidence
vs
60% evidence
```

consider:

```text id="jy1ujj"
20%
 ↓
40%
 ↓
60%
 ↓
80%
 ↓
100%
```

for the same real cell.

Let the state inferred with evidence fraction \(p\) be:

\[
z_i(p).
\]

Then look at how the state converges as evidence increases.

For an easy cell:

```text id="app1qf"
20%  --------\
40%           \
60%             → stable state
80%             →
100%            →
```

For a difficult cell:

```text id="rnieyn"
20% ──► large change
40% ──► large change
60% ──► still changes
80% ──► changes
100%
```

That gives us something richer than a single error.

We can define biological information stability conceptually as:

\[
C_i(p)
=
\|z_i(p)-z_i(100)\|.
\]

And even more useful:

\[
\Delta_i(p\rightarrow p')
=
\|z_i(p')-z_i(p)\|.
\]

Then biological uncertainty means:

> **How much is my inferred biological state expected to change if substantially more relevant molecular evidence becomes available?**

That definition survives:

- different panels;
- spatial assays;
- different technologies;
- different sequencing depths;
- future multimodal evidence.

It does not depend on “40%” being special.

---

# 5. Do the same thing separately for measurement quality

For the exact same real cell:

```text id="gau3t0"
25% count depth
50%
75%
100%
```

giving:

\[
z_i^{depth}(p).
\]

Now we have two independent response curves.

### Evidence curve

More **biological information**.

\[
z(\text{more genes/evidence})
\]

### Measurement curve

Better measurement of **the same information**.

\[
z(\text{greater depth})
\]

This gives us an experimental way of separating:

\[
U_{\text{bio}}
\]

from:

\[
U_{\text{measurement}}.
\]

That is better than asking a neural network to discover the distinction without supervision.

---

# 6. The really interesting quantity may be **information efficiency**

Different cells may require different amounts of evidence before their state stabilizes.

We could calculate something like:

> minimum evidence required for the state to enter a stable neighborhood of its high-evidence reference.

Not necessarily make this a production metric yet, but scientifically it is fascinating.

For example:

```text id="200jle"
Cell A stabilizes with 35% evidence.
Cell B requires 75%.
Cell C never fully stabilizes.
```

That is telling us something about **how redundantly the cell's molecular state is encoded**.

It could eventually matter greatly for targeted panels and spatial assays.

---

# 7. Add one more transfer test: **leave an entire dataset family out**

Leave-one-matrix-out is useful but may be too easy.

Matrices from the same study can share:

- laboratory;
- processing;
- chemistry;
- sample preparation;
- donor population.

So I'd use three increasingly difficult tests:

\[
\text{held-out donor}
\]

then:

\[
\text{held-out matrix}
\]

then:

\[
\boxed{\text{held-out dataset/study}}
\]

and, where scientifically possible:

\[
\boxed{\text{held-out technology}}
\]

The last two are the most informative.

If the state works on a dataset family that did not participate in defining the basis, that's much stronger evidence of a reusable biological coordinate system.

---

# 8. We should distinguish **interpolation uncertainty from extrapolation uncertainty**

This improves our domain-uncertainty concept.

A new cell might be:

### Familiar measurement + familiar biology

```text id="zamw10"
low domain concern
```

### Familiar measurement + unusual biology

```text id="j1lyw5"
possibly important new biology
```

### Unfamiliar measurement + familiar-looking biology

```text id="8jxhft"
measurement/domain concern
```

### Unfamiliar measurement + unfamiliar biology

```text id="7bbmvd"
high uncertainty
```

A generic OOD score would mix these together.

So domain support should eventually have at least two axes:

\[
D_{\text{measurement}}
\]

and

\[
D_{\text{biological support}}.
\]

Otherwise a rare and potentially important biological state could be incorrectly dismissed as a technical outlier.

That's especially important later when we're looking for **rare vulnerability or resilience states**.

---

# 9. Don't make donor variability disappear

This deserves emphasis because FHRA saw considerable donor imprint.

Some donor variation is nuisance.

But some could be exactly the biology we ultimately care about.

If 149 TRAIN donors teach us:

```text id="yxu2pe"
common biology
+
population variation
```

then a new donor shouldn't simply be projected toward the population average.

A good model should say:

> This donor contains a somewhat unusual but well-measured biological state.

instead of:

> Domain shift; correct it away.

This is another reason domain uncertainty and biological novelty must not be the same thing.

---

# 10. Sampling deserves a hierarchical design

When production training eventually begins, I would avoid both extremes:

```text id="8kksq1"
sample cells uniformly
```

because huge datasets dominate,

and:

```text id="0y9f07"
sample datasets uniformly
```

because tiny datasets can become massively overrepresented.

A better eventual structure is hierarchical:

```text id="wsqjp0"
dataset
   ↓
donor
   ↓
cell
```

with bounded weighting at each level.

For example conceptually:

\[
P(\text{dataset})
\propto
N_{\text{dataset}}^\alpha
\]

with \(0<\alpha<1\).

But **we should predeclare rather than tune \(\alpha\) on biological outcomes**.

The important principle is:

> six million cells should not secretly mean “the largest dataset defines biology.”

---

# 11. Another improvement: keep the molecular ledger as the **high-resolution escape hatch**

This is why I am not particularly worried that PCA160 captures only ~42% of pooled variance.

We are not throwing away everything else.

We have:

```text id="3xeq95"
4096 × 160 molecular ledger
        +
160-D accountable global biological state
```

The 160-D state doesn't need to contain every transcriptomic detail.

It needs to provide a stable, accountable global coordinate system.

The ledger retains detailed molecular information.

That multi-resolution arrangement is a major strength.

So I would explicitly formalize:

\[
\boxed{
\text{ledger}=\text{fine molecular state}
}
\]

\[
\boxed{
\text{160-D state}=\text{global accountable state}
}
\]

rather than judging the whole architecture based on PCA explained variance.

---

# 12. One future idea I would prepare for—but NOT implement yet

Eventually we may find one global state insufficient.

Then a natural extension is:

\[
z=
(z_{\text{shared}},z_{\text{context}})
\]

where:

### Shared state

biology recurring across donors/tissues/technologies.

### Context state

legitimate context-dependent biology.

The crucial thing is that **measurement/domain effects still stay outside both**.

But I would only implement this if the next domain-direction analysis shows that real biology and technical acquisition cannot be adequately represented in the current single state.

Don't add it preemptively.

---

# Where I think we are now

I would rank the remaining ideas like this:

| Improvement | Priority |
|---|---|
| Observation-process/operator abstraction | **Very high** |
| Donor + matrix balanced reproducible basis | **Very high** |
| Basis/subspace stability audit | **Very high** |
| Evidence-vs-depth convergence curves | **Very high** |
| Conditional technology-imprint analysis | **Very high** |
| Held-out dataset/technology transfer | **Very high** |
| QC must earn measurement-channel access | **High** |
| Separate biological novelty vs measurement OOD | **High** |
| Hierarchical production sampling | **Before real training** |
| Shared/context latent decomposition | **Only if evidence demands it** |
| New nonlinear architecture | **No** |
| Pathology | **Absolutely not yet** |

So yes, we can still make it better—but now the improvements are increasingly about **making the scientific meaning of the state and uncertainty harder to fake**, rather than adding more neural machinery.

The version I would ultimately want to freeze has a very simple conceptual promise:

> **The molecular ledger preserves what was measured. The global state captures reproducible biology. The observation model knows how the experiment measured it. Biological uncertainty says how much the state could change with better biological evidence. Measurement uncertainty says how much it could change if the same biology were remeasured. Domain support says whether the observation regime itself is familiar.**

If we can demonstrate those properties pathology-blind across donors, matrices and technologies, I think we will have pushed the architecture about as far as we responsibly should before starting real foundation optimization. memcite